Project Orbis – a sponsor’s perspective on the collaborative international review process

AdobeStock_831949741 (1)

Project Orbis provides a framework for concurrent submission and review of regulatory dossiers with member agencies in the project, and has the goal of providing faster patient access to innovative cancer therapies with a high unmet medical need across its participating countries. A sponsor’s decision to participate in Project Orbis is influenced by a number of factors including the complexity of the application, the potential for faster review timelines and resource availability, both internally and within participating authorities, which in turn have an impact on which countries and Orbis types are selected and ultimately whether a sponsor will be able to participate.

This article summarises AstraZeneca’s experiences to date with Project Orbis, including strategic considerations for participation, challenges and opportunities faced during the review, as well as considerations for the future direction of the programme.

How to read this journal article 

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to registered users and TOPRA members.

Already a member or have an account? Sign in.


Free access to selected content

Register now to continue to access industry news, editorials and podcasts plus one member-only journal article each month.

  • Create your own library to save your favourite content.
Create a free account

2. Members login

Already a TOPRA member?

Log-in now using your MyTOPRA credentials, for unlimited access to all Regulatory Rapporteur journal articles, the online archive and latest industry news and podcasts.



Special offer on
TOPRA membership

Join TOPRA today and get membership until the end of 2025 for the exclusive rate of £290.

In addition to unlimited access to Regulatory Rapporteur content, as a TOPRA member you will also be able to enjoy a wide range of benefits including career boosting resources, savings on our events and training, and access to our regional networks and special interest groups.

This offer ends 31 July 2024

Become a member